Stockreport

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

Prevail Therapeutics Inc.  (PRVL) 
Last prevail therapeutics inc. earnings: 11/12 09:30 am Check Earnings Report
PDF NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene [Read more]